Working… Menu

A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01464034
Recruitment Status : Unknown
Verified October 2017 by Criterium, Inc..
Recruitment status was:  Recruiting
First Posted : November 3, 2011
Last Update Posted : October 18, 2017
Celgene Corporation
Information provided by (Responsible Party):
Criterium, Inc.

No Study Results Posted on for this Study
Recruitment Status : Unknown
Estimated Primary Completion Date : December 2017
Estimated Study Completion Date : June 2018